Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/WDR59_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/WDR59_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/WDR59_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/WDR59_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007149626 | Esophagus | HGIN | cellular response to external stimulus | 71/2587 | 320/18723 | 2.77e-05 | 7.19e-04 | 71 |
GO:003166820 | Esophagus | HGIN | cellular response to extracellular stimulus | 56/2587 | 246/18723 | 9.05e-05 | 1.97e-03 | 56 |
GO:003166920 | Esophagus | HGIN | cellular response to nutrient levels | 47/2587 | 215/18723 | 8.20e-04 | 1.07e-02 | 47 |
GO:003166726 | Esophagus | HGIN | response to nutrient levels | 89/2587 | 474/18723 | 1.41e-03 | 1.64e-02 | 89 |
GO:000926719 | Esophagus | HGIN | cellular response to starvation | 34/2587 | 156/18723 | 4.21e-03 | 3.77e-02 | 34 |
GO:004259418 | Esophagus | HGIN | response to starvation | 41/2587 | 197/18723 | 4.34e-03 | 3.84e-02 | 41 |
GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:0009267110 | Esophagus | ESCC | cellular response to starvation | 110/8552 | 156/18723 | 2.63e-10 | 7.37e-09 | 110 |
GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
GO:19909284 | Esophagus | ESCC | response to amino acid starvation | 37/8552 | 49/18723 | 2.05e-05 | 1.78e-04 | 37 |
GO:00319294 | Esophagus | ESCC | TOR signaling | 79/8552 | 126/18723 | 8.57e-05 | 6.21e-04 | 79 |
GO:00341984 | Esophagus | ESCC | cellular response to amino acid starvation | 34/8552 | 46/18723 | 9.39e-05 | 6.70e-04 | 34 |
GO:00320061 | Esophagus | ESCC | regulation of TOR signaling | 63/8552 | 104/18723 | 1.55e-03 | 7.29e-03 | 63 |
GO:00320082 | Esophagus | ESCC | positive regulation of TOR signaling | 31/8552 | 47/18723 | 4.01e-03 | 1.62e-02 | 31 |
GO:00316677 | Liver | NAFLD | response to nutrient levels | 85/1882 | 474/18723 | 8.23e-08 | 7.09e-06 | 85 |
GO:00714967 | Liver | NAFLD | cellular response to external stimulus | 51/1882 | 320/18723 | 6.21e-04 | 8.18e-03 | 51 |
GO:00425945 | Liver | NAFLD | response to starvation | 33/1882 | 197/18723 | 2.35e-03 | 2.21e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR59 | SNV | Missense_Mutation | | c.613C>T | p.His205Tyr | p.H205Y | Q6PJI9 | protein_coding | tolerated(1) | benign(0) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
WDR59 | SNV | Missense_Mutation | novel | c.227N>C | p.Tyr76Ser | p.Y76S | Q6PJI9 | protein_coding | tolerated(0.09) | benign(0.139) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
WDR59 | insertion | In_Frame_Ins | novel | c.637_638insGGC | p.Asp213delinsGlyHis | p.D213delinsGH | Q6PJI9 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
WDR59 | insertion | Frame_Shift_Ins | novel | c.635_636insTGGGATGTTCACCCTTGGTCAGAATGATGGC | p.Gln212HisfsTer69 | p.Q212Hfs*69 | Q6PJI9 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
WDR59 | insertion | Frame_Shift_Ins | novel | c.1826_1827insGCCTCCCG | p.Glu610ProfsTer62 | p.E610Pfs*62 | Q6PJI9 | protein_coding | | | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
WDR59 | insertion | In_Frame_Ins | novel | c.1825_1826insTTCTTGTGCCTC | p.Lys609delinsIleLeuValProGln | p.K609delinsILVPQ | Q6PJI9 | protein_coding | | | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
WDR59 | insertion | In_Frame_Ins | novel | c.1645_1646insCAGTACTAGGGAACACCTACATTACAC | p.Tyr549delinsSerValLeuGlyAsnThrTyrIleThrHis | p.Y549delinsSVLGNTYITH | Q6PJI9 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR59 | insertion | Nonsense_Mutation | novel | c.1272_1273insATACAAAAAAGATAGATTTTTCTGTTAGTATAAAATGATA | p.His425IlefsTer5 | p.H425Ifs*5 | Q6PJI9 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR59 | insertion | Nonsense_Mutation | novel | c.449_450insACATGCTGGGGAAGCCTTATGTGGCAGAAGCCCTCTGCCTTAGA | p.Ala151HisfsTer14 | p.A151Hfs*14 | Q6PJI9 | protein_coding | | | TCGA-AO-A0J7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
WDR59 | insertion | Frame_Shift_Ins | novel | c.1364_1365insTAAGGTACTGACGTTTCTCATGGAGCAAGTGGTGTTGGGG | p.Thr456LysfsTer18 | p.T456Kfs*18 | Q6PJI9 | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |